Want to see VTRS full AI Analyst Report?
VTRS Stock Chart & Stats
$16.72
-$0.04(-0.23%)
At close: 4:00 PM EDT
$16.72
-$0.04(-0.23%)
Day’s Range― - ―
52-Week Range$9.92 - $18.67
Previous CloseN/A
Volume7.37M
Average Volume (3M)8.45M
Market Cap
$20.93B
Enterprise Value$30.69B
Total Cash (Recent Filing)$1.51B
Total Debt (Recent Filing)$13.63B
Price to Earnings (P/E)―
Beta0.93
Next Earnings
Nov 05, 2026EPS Estimate
0.64Next Dividend Ex-DateN/A
Dividend Yield2.57%
Share Statistics
EPS (TTM)-0.36
Shares Outstanding1,148,590,800
10 Day Avg. Volume8,320,992
30 Day Avg. Volume8,453,122
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.99
Price to Sales (P/S)1.02
P/FCF Ratio7.52
Enterprise Value/Market Cap1.47
Enterprise Value/Revenue2.08
Enterprise Value/Gross Profit5.98
Enterprise Value/Ebitda11.30
Forecast
1Y Price Target
$20.00Price Target Upside19.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)2.52
Revenue Forecast (FY)$14.79B
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationRobust operating and free cash flow provides Viatris with internal funding for debt repayment, shareholder returns, and portfolio investment. The combination of strong cash earnings and working-capital discipline supports financial flexibility even while reported earnings remain under pressure.
Raised Operating OutlookManagement’s higher 2026 guidance, following a quarterly revenue, EBITDA, and EPS beat, indicates confidence in execution and portfolio momentum. Continued adjusted profit growth would strengthen cash generation and support a more durable recovery in operating performance.
Accretive Portfolio ExpansionThe proposed Pacira acquisition broadens Viatris beyond its traditional generic base with established, patent-protected non-opioid pain products. Viatris expects to use its intellectual property expertise and global infrastructure to extend product lifecycles, expand reach, and capture synergies.
Bears Say
Weak GAAP ProfitabilityNegative operating profit and net income weaken the quality and consistency of Viatris’s reported earnings despite solid adjusted EBITDA. Lower gross margins and historical earnings volatility may limit retained capital, reduce resilience, and make sustainable shareholder returns more difficult.
Elevated LeverageViatris has improved its leverage trajectory, but debt remains substantial relative to equity and creates an ongoing obligation against cash flow. This can constrain capital allocation and leave less flexibility for acquisitions, investment, or unexpected operating setbacks.
Competitive And Policy PressureCompetition in established brands and high-margin products can produce price erosion and weaker product contributions over time. This pressure is compounded by changing China procurement policy, which may reduce hospital-channel volumes and make growth and margin improvement harder to sustain.
Viatris News
VTRS FAQ
What was Viatris’s price range in the past 12 months?
Viatris lowest stock price was $9.92 and its highest was $18.66 in the past 12 months.
What is Viatris’s market cap?
Viatris’s market cap is $20.93B.
When is Viatris’s upcoming earnings report date?
Viatris’s upcoming earnings report date is Nov 05, 2026 which is in 18 days.
How were Viatris’s earnings last quarter?
Viatris released its earnings results on Aug 06, 2026. The company reported $0.69 earnings per share for the quarter, beating the consensus estimate of $0.601 by $0.089.
Is Viatris overvalued?
According to Wall Street analysts Viatris’s price is currently Undervalued.
Does Viatris pay dividends?
Viatris pays a Quarterly dividend of $0.12 which represents an annual dividend yield of 2.57%. See more information on Viatris dividends here
What is Viatris’s EPS estimate?
Viatris’s EPS estimate is 0.64.
How many shares outstanding does Viatris have?
Viatris has 1,148,590,800 shares outstanding.
What happened to Viatris’s price movement after its last earnings report?
Viatris reported an EPS of $0.69 in its last earnings report, beating expectations of $0.601. Following the earnings report the stock price went down -7.706%.
Which hedge fund is a major shareholder of Viatris?
Currently, no hedge funds are holding shares in VTRS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Viatris Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$20.00 (19.62% Upside)
$20.00 (19.62% Upside)
Blogger Sentiment
Bullish
VTRS Sentiment 67%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 147.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.5%
Last 30 Days ▲ 0.4%
Last 30 Days ▲ 0.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
91.25%
12-Months-Change
Fundamentals
Return on Equity
-2.79%
Trailing 12-Months
Asset Growth
-8.77%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Viatris
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.
VTRS Company Deck
VTRS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed predominantly positive operational and strategic momentum: the company beat expectations in Q2 on revenue, EBITDA and EPS, raised full-year guidance across key metrics, showed margin improvement, strong cash generation, aggressive capital returns, meaningful pipeline and regulatory progress (Gwyn Lo approval, Nefecon topline, Phase III programs on track). Offsetting this, notable near-term challenges include Nashik manufacturing disruptions (with a $100–$150 million H2 revenue headwind), emerging markets supply constraints, competitive pressure in some developed-market products, and China procurement policy uncertainty that may moderate future growth. Overall, management framed the challenges as mostly short-term and fully considered in the updated guidance while emphasizing long-term growth opportunities and financial flexibility.View all VTRS earnings summariesVTRS Net sales Breakdown
64.45% Brands
35.55% Generics
VTRS Stock 12 Month Forecast
Average Price Target
$20.00
▲(19.62% Upside)
Technical Analysis
Ownership Overview
0.28% Insiders
27.80% Mutual Funds
1.80% Other Institutional Investors
42.15% Public Companies and
Individual Investors